Healthcare · Biotechnology
ABL Bio Inc.
298380KRX₩39,200−₩1,800 (−4.39%)Market closed
Price Chart
Daily
Key facts
- Market Cap
- ₩2.19T
- P/E
- −53.4x
- P/B
- 13.05x
- ROE
- −23.5%
ABL Bio Inc.
Healthcare · Biotechnology · FY 2025
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
- CEO
- 이상훈
- Employees
- 102
- Website
- ablbio.com
Company Statistics
Valuation
P/E
−53.4x
P/B
13.05x
P/S
25.45x
EV/EBITDA
−58.2x
P/FCF
−32.6x
Margins
Gross
100.0%
EBITDA
−42.6%
Operating
−50.8%
Pre-Tax
−47.7%
Net
−47.7%
Returns
ROA
−14.8%
ROE
−23.5%
ROIC
−14.4%
Growth (CAGR)
Rev 3Yr
5.6%
Rev 5Yr
57.8%
Op Inc 3Yr
—
Net Inc 3Yr
—
Financial Health
Cash & Cash Equivalents
₩111.98B
Net Debt
₩12.25B
Debt/Equity
79.3%
Interest Cov
—
Profile
Revenue
₩79.35B
Shares Out
56.0M